10x Genomics (TXG) Tops Q4 EPS by 4c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus

10x Genomics (NASDAQ: TXG) reported Q4 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $75.3 million versus the consensus estimate of $70 million.

Recent Highlights

• Revenue of $75.3 million for the fourth quarter and $245.9 million for the full year of 2019, representing 49% and 68% increases, respectively, over the corresponding periods of 2018
• Total of 1,666 Chromium instruments sold as of December 31, 2019
• Initiated shipments of the Visium Spatial Gene Expression Solution

GUIDANCE:

10x Genomics sees FY2020 revenue of $350-360 million, versus the consensus of $346.18 million.

• 10x Genomics expects full year 2020 revenue to be in the range of $350 million to $360 million, representing 42% to 46% growth over full year 2019 revenue.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• RBC Capital Starts Molina Healthcare (MOH) at Sector Perform
• FirstCash to acquire UK pawn operator Ramsdens for £206 million